Certara, Inc. Common Stock (CERT) — Analysis Summary
Certara, Inc. Common Stock (CERT) has a market cap of $1.22B with year-over-year revenue growth of +8.7%. Net margin stands at -0.4%. The stock trades at a P/E ratio of -80.8.
Key Takeaways
- Revenue changed +8.7% year-over-year
- Net margin of -0.4%
- P/E ratio of -80.8
Compared to other companies in the SERVICES-PREPACKAGED SOFTWARE sector, CERT posted revenue growth of +8.7% and trades at a P/E of -80.8.
Certara, Inc. Common Stock (CERT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.5x — earnings do not cover interest payments
Net income fell 846.8% vs the prior period.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Sector
SERVICES-PREPACKAGED SOFTWARE
Employees
1,576
Headquarters
RADNOR, PA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.